雄激素受体驱动聚胺合成,为前列腺癌造成脆弱性
medRxiv : the preprint server for health sciences
|December 23, 2024
概括
超生理性雄激素 (SPA) 通过激活雄激素受体 (AR) 来调节ODC1.1,从而促进前列腺癌中的聚胺合成. 抑制聚胺合成增强了SPA的有效性,揭示了治疗的脆弱性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 代谢途径 代谢途径
背景情况:
- 超生理性雄激素 (SPA) 治疗,包括双极雄激素疗法 (BAT),矛盾地抑制了AR活性瘤中割抵抗性前列腺癌 (CRPC) 的生长.
- 由SPA引起的代谢变化及其对CRPC进展和治疗反应的影响仍然不太清楚.
研究的目的:
- 调查前列腺癌模型中SPA诱导的代谢变化,特别是聚胺合成.
- 阐明SPA影响聚胺代谢的机制及其在CRPC进展中的作用.
- 评估与SPA结合向聚胺合成的治疗潜力.
主要方法:
- 利用前列腺癌模型来评估SPA对细胞内和分泌的多氨酸的影响.
- 研究了雄激素受体 (AR) 结合增强剂位点的作用,该增强剂位点在甲基尼氨酸脱酶1 (ODC1) 促进剂的上游.
- 采用dCas9-KRAB介导的AR调节抑制和二甲基诺尼丁 (DFMO) 抑制ODC活动.
- 评估了聚胺枯竭对S-adenosylmethionine脱碳酶1 (AMD1) 活性和全球蛋白质甲基化的影响.
- 在转移性CRPC患者中进行了BAT和DFMO结合的I期临床试验,包括药理动力学研究.
主要成果:
- 在前列腺癌模型中,SPA显著增加了细胞内和分泌的多氨酸.
- 在增强剂位点的AR结合增加了ODC1的丰富度,从而从阿金氨酸中驱动新的聚胺合成.
- 使用DFMO抑制AR驱动的ODC1或ODC活性,提高了SPA治疗的疗效.
- SPA增加了AMD1活性,部分原因是AR刺激和减少的聚胺反,导致S-adenosylmethionine耗尽和降低全球蛋白质甲基化.
- 在患者的药理学研究显示,有效的血聚胺耗尽与BAT + DFMO组合.
结论:
- 雄激素受体 (AR) 在前列腺癌中强烈刺激聚胺合成.
- 在AR驱动的前列腺癌中,SPA诱导的聚胺合成代表了关键的代谢脆弱性.
- 针对聚胺合成,例如使用DFMO,与SPA (BAT) 结合,为转移性CRPC提供了一个有希望的治疗策略.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.8K
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.0K
相关概念视频
Internal Receptors
69.4K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
69.4K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Biosynthesis of Nucleic Acids
2
Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...
2
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
